Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study

被引：0
|
作者：
Selmaj, Krzysztof [1 ,2 ]
Langdon, Dawn [3 ]
Brochet, Bruno [4 ]
Solari, Alessandra [5 ]
Havrdova, Eva Kubala [6 ,7 ]
Patti, Francesco [8 ,9 ]
Piehl, Fredrik [10 ]
Smyk, Andrzej [11 ]
Lehn, Annette [11 ]
Nolting, Axel [11 ]
Montalban, Xavier [12 ]
Lechner-Scott, Jeannette [13 ,14 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Olsztyn, Poland
[3] Royal Holloway Univ London, Dept Psychol, Egham, Surrey, England
[4] Univ Bordeaux, INSERM U 1215, Bordeaux, France
[5] Fdn IRCCS Ist Neurol Carlo Besta, Unit Neuroepidemiol, Milan, Italy
[6] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[7] Ctr Clin Neurosci, Prague, Czech Republic
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol, GF Ingrassia, Catania, Italy
[9] Univ Catania, Azienda Osped Univ Policlin G Rodolico San Marco, Catania, Italy
[10] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[11] Merck Healthcare KGaA, Darmstadt, Germany
[12] Univ Hosp Vall dHebron, Dept Neurol Neuroimmunol, Ctr Multiple Sclerosis Catalonia Cemcat, Barcelona, Spain
[13] Univ Newcastle, Newcastle, NSW, Australia
[14] John Hunter Hosp, Div Neurol, Newcastle, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P846/1650
引用
收藏
页码：655 / 657
页数：3
相关论文
共 50 条
  • [21] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [22] Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results
    Oh, Jiwon
    Syed, Sana
    Li, Tong
    Salloum, Naji
    Turner, Timothy J.
    Fox, Robert J.
    NEUROLOGY, 2023, 100 (17)
  • [23] 4-Year Results from the Long-Term Extension of the Belatacept BENEFIT Study
    Larsen, C.
    Alberu, J.
    Massari, P.
    Reyes Acevedo, R.
    Kamar, N.
    Lin, C. -S.
    Harler, M. B.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 82 - 82
  • [24] Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
    Takahiko Saida
    Yasuto Itoyama
    Seiji Kikuchi
    Qi Hao
    Takayoshi Kurosawa
    Kengo Ueda
    Lixin Zhang Auberson
    Isao Tsumiyama
    Kazuo Nagato
    Jun-ichi Kira
    BMC Neurology, 17
  • [25] Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study
    Saida, Takahiko
    Itoyama, Yasuto
    Kikuchi, Seiji
    Hao, Qi
    Kurosawa, Takayoshi
    Ueda, Kengo
    Auberson, Lixin Zhang
    Tsumiyama, Isao
    Nagato, Kazuo
    Kira, Jun-ichi
    BMC NEUROLOGY, 2017, 17
  • [26] Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience
    Yamout, Bassem I.
    Shatila, Ahmad
    Inshasi, Jihad
    Hassan, Ali Mohammed Ali
    Szolics, Mikolas
    Hassan, Ahmed
    Farw, Ahmed
    Ismail, Ghida
    Zeineddine, Maya
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 379 - 379
  • [27] Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study
    De Stefano, Nicola
    Achiron, Anat
    Barkhof, Frederik
    Chan, Andrew
    Derfuss, Tobias
    Hodgkinson, Suzanne
    Leocani, Letizia
    Montalban, Xavier
    Prat, Alexandre
    Schmierer, Klaus
    Sellebjerg, Finn
    Vermersch, Patrick
    Wiendl, Heinz
    Keller, Birgit
    Smyk, Andrzej
    Gardner, Lidia
    NEUROLOGY, 2023, 100 (17)
  • [28] Early onset of action and sustained efficacy of MRI outcomes during cladribine tablets treatment in highly active relapsing multiple sclerosis: results of the 2-year MAGNIFY-MS study
    De Stefano, N.
    Achiron, A.
    Barkhof, F.
    Chan, A.
    Derfuss, T.
    Hodgkinson, S.
    Leocani, L.
    Montalban, X.
    Prat, A.
    Schmierer, K.
    Sellebjerg, F.
    Vermersch, P.
    Wiendl, H.
    Keller, B.
    Smyk, A.
    Gardner, L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 629 - 631
  • [29] Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
    Rejdak, Konrad
    Zasybska, Adriana
    Pietruczuk, Aleksandra
    Baranowski, Dariusz
    Szklener, Sebastian
    Kaczmarek, Magda
    Stelmasiak, Zbigniew
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [30] A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study
    Giovannoni, Gavin
    Boyko, Alexey
    Correale, Jorge
    Edan, Gilles
    Freedman, Mark S.
    Montalban, Xavier
    Rammohan, Kottil
    Stefoski, Dusan
    Yamout, Bassem
    Leist, Thomas
    Aydemir, Aida
    Borsi, Laszlo
    di Cantogno, Elisabetta Verdun
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2023, 13 (05) : 261 - 268
12345